Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650468 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 397
- Enrollment target
NCT00650468 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 397 participants.
The verdict
NCT00650468, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 397 participants
- Enrollment target
Study Summary
A study comparing the early withdrawal of steroids to long-term maintenance steroid therapy in Kidney Transplant Patients receiving Prograf and Cellcept
Interventions
- DRUG tacrolimus
- DRUG CellCept
- DRUG steroids (methylprednisone or prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 1999-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650468
The ClinicalTrials.gov registry entry for NCT00650468 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tacrolimus is the first listed.
NCT00650468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650468 about?
NCT00650468 is a clinical study titled "A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients". A study comparing the early withdrawal of steroids to long-term maintenance steroid therapy in Kidney Transplant Patients receiving Prograf and Cellcept
What is the current status of trial NCT00650468?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 397 participants. The study started on 1999-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00650468?
The interventions under investigation include: tacrolimus (DRUG), CellCept (DRUG), steroids (methylprednisone or prednisone) (DRUG).
Who is sponsoring clinical trial NCT00650468?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.